Contact Us
Drug Search Results
More Filters [+]

Dextran

Alternative Names: dextran, infed, photrexa viscous
Latest Update: 2024-12-09
Latest Update Note: News Article

Product Description

Mechanisms of Action: Thrombin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Korea | Lithuania | Malaysia | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Anemia

Known Adverse Events: Hypotension | Back Pain | Chest Pain | Dizziness | Pain Unspecified | Pruritus | Dyspnea | Flushing

Company: Bows
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dextran

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Type 1 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2016-001867-35

P2

Active, not recruiting

Type 1 Diabetes

2020-10-24

Recent News Events

Date

Type

Title

12/09/2024

News Article

 Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

12/04/2024

News Article

 bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

11/05/2024

News Article

 bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

10/28/2024

News Article

 AltruBio Presents New In Vivo data for ALTB-268 at the 9th FIMSA 2024 Congress

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions